In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Summit Therapeutics Inc’s stock clocked out at $24.20, down -13.63% from its previous closing price of $28.02. In other words, the price has decreased by -$13.63 from its previous closing price. On the day, 4.37 million shares were traded.
Ratios:
To gain a deeper understanding of SMMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.63 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on March 26, 2025, Upgraded its rating to Buy and sets its target price to $35 from $23 previously.
On March 12, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $30.Evercore ISI initiated its Outperform rating on March 12, 2025, with a $30 target price.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $2.10. The 50-Day Moving Average of the stock is 12.15%, while the 200-Day Moving Average is calculated to be 26.60%.
Shares Statistics:
A total of 741.61M shares are outstanding, with a floating share count of 111.14M. Insiders hold about 84.93% of the company’s shares, while institutions hold 12.80% stake in the company.
